What is Vitiligo?
Vitiligo is a chronic skin condition characterized by the loss of skin pigmentation, leading to the appearance of white patches on different areas of the body. It occurs when melanocytes—the cells responsible for producing skin pigment—are destroyed by the immune system. Vitiligo affects approximately 0.5–2% of the global population and can occur in people of any age, sex, or ethnicity.
Although vitiligo is not contagious and does not cause physical pain, it can significantly affect quality of life and emotional well-being. Current treatment options are limited and relapses are common, highlighting the need for new, more effective therapies.
Conditions of participation:
age 18-75
diagnosed with nonsegmental vitiligo for at least 3 months
visible vitiligo lesions affecting 4–60% of body surface area, including at least 0.5% on the face
willingness not to use other treatments for vitiligo during the study
agree to undergo skin biopsies during the study
We provide participants with
comprehensive health assessment
(including: dermatological examination and assessment of vitiligo, photographic documentation of skin lesions, ECG, chest X-ray, extended blood and urine tests)
access to innovative treatment
ongoing medical care throughout the study period
You can find other benefits of participating in a clinical trial on the “What are clinical trials?” tab.
Study duration
The total study duration is approximately 48 weeks, including:
• Screening period: up to 5 weeks,
• Treatment period: 24 weeks,
• Follow-up period: 19 weeks after the last treatment visit.
Join us!
Form
Principal Investigator
dr n. med. Justyna Kwapisz
